Document Detail


A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria.
MedLine Citation:
PMID:  2196028     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Acute intermittent porphyria is a genetic disease in which endogenous hormones affect clinical expression. Premenstrual exacerbations can occur, sometimes often, in women with this disease. Gonadotropin releasing hormone analogues can prevent ovulation by reducing secretion of luteinizing hormone and follicle-stimulating hormone. In six patients with well-documented acute intermittent porphyria and frequent cyclical exacerbations, daily administration of an agonistic gonadotropin releasing hormone analogue, ([ImBzl]-D-His6,Pro9-NET)gonadotropin releasing hormone, intranasally or subcutaneously for as long as 26 months reduced or eliminated premenstrual attacks and caused only minor side effects. Adjustments in dosage or route of administration were sometimes needed. We conclude that endocrine manipulation by treatment with a gonadotropin releasing hormone agonist will prevent neurovisceral attacks of acute intermittent porphyria due to cyclical changes in endogenous hormones and is a safe alternative to exogenous steroids, which may induce attacks of this disease.
Authors:
K E Anderson; I M Spitz; C W Bardin; A Kappas
Related Documents :
7579908 - Stability of urinary female reproductive hormones stored under various conditions.
20980998 - Twice-weekly administration of kisspeptin-54 for 8 weeks stimulates release of reproduc...
21139318 - Serum fibroblast growth factor-23 levels and progression of aortic arch calcification i...
21318058 - The relationship between serum ghrelin levels and hair zinc concentrations in children.
11434358 - Relationships between homocysteine and related amino acids in chronic hemodialysis pati...
12077728 - Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with ...
Publication Detail:
Type:  Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Archives of internal medicine     Volume:  150     ISSN:  0003-9926     ISO Abbreviation:  Arch. Intern. Med.     Publication Date:  1990 Jul 
Date Detail:
Created Date:  1990-08-13     Completed Date:  1990-08-13     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372440     Medline TA:  Arch Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1469-74     Citation Subset:  AIM; IM    
Affiliation:
Rockefeller University Hospital, New York, NY.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aminolevulinic Acid / urine
Female
Gonadotropin-Releasing Hormone / adverse effects,  analogs & derivatives*,  therapeutic use
Humans
Menstrual Cycle / physiology
Periodicity
Porphobilinogen / urine
Porphyrias / physiopathology,  prevention & control*,  urine
Grant Support
ID/Acronym/Agency:
AM-32890/AM/NIADDK NIH HHS; ES-01055/ES/NIEHS NIH HHS; FD-R-000307/FD/FDA HHS
Chemical
Reg. No./Substance:
106-60-5/Aminolevulinic Acid; 33515-09-2/Gonadotropin-Releasing Hormone; 487-90-1/Porphobilinogen; 76712-82-8/histrelin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cystic thyroid nodules. The dilemma of malignant lesions.
Next Document:  Aerobic nitrate and nitrite reduction in continuous cultures of Escherichia coli E4.